Puneet Souda
Stock Analyst at Leerink Partners
(1.59)
# 3,477
Out of 5,102 analysts
218
Total ratings
49.15%
Success rate
-0.7%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $578.90 | +0.19% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $74.83 | +4.24% | 8 | Oct 21, 2025 | |
| GH Guardant Health | Maintains: Outperform | $70 → $75 | $101.38 | -26.02% | 6 | Sep 25, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $9.64 | +65.98% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $6.40 | +87.50% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $7.55 | +5.96% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $11.77 | -23.53% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $7.30 | +187.67% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $42.22 | -5.26% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $231.05 | -35.08% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $392.21 | -4.39% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $37.97 | -7.82% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $142.87 | +1.49% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $232.37 | +29.10% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $136.44 | +83.23% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $60.26 | +82.54% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $101.36 | -26.01% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $161.66 | +23.72% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $3.74 | +381.28% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $2.16 | +177.78% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $32.12 | -6.60% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $46.37 | +87.62% | 13 | May 5, 2022 |
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $578.90
Upside: +0.19%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $74.83
Upside: +4.24%
Guardant Health
Sep 25, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $101.38
Upside: -26.02%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $9.64
Upside: +65.98%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $6.40
Upside: +87.50%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $7.55
Upside: +5.96%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $11.77
Upside: -23.53%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $7.30
Upside: +187.67%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $42.22
Upside: -5.26%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $231.05
Upside: -35.08%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $392.21
Upside: -4.39%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $37.97
Upside: -7.82%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $142.87
Upside: +1.49%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $232.37
Upside: +29.10%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $136.44
Upside: +83.23%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $60.26
Upside: +82.54%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $101.36
Upside: -26.01%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $161.66
Upside: +23.72%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $3.74
Upside: +381.28%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $2.16
Upside: +177.78%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $32.12
Upside: -6.60%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $46.37
Upside: +87.62%